+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 65Years
All Genders
ID07221877

Open-Label 12-Month Study Evaluating KarXTs Impact on Urinary Safety and Voiding in Schizophrenia

Led by Bristol-Myers Squibb · Updated on 2026-10-19

60

Participants Needed

16

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effect of KarXT on voiding dynamics and urological safety in adults aged 18 to 65 years with schizophrenia diagnosed according to DSM-5 criteria. This Phase 4, open-label, multicenter trial aims to better understand how KarXT affects urinary function and safety over a 12-month period in this population. Participants will receive KarXT xanomelinetrospium chloride at specified doses on specified days during the study. The study lasts up to 12 months, during which urological safety and voiding function will be carefully monitored. The trial does not include a placebo group and all participants receive the study drug. During the study, participants will have regular assessments of voiding dynamics such as maximum urinary flow rate Qmax and post-void residual volume PVR. Additional monitoring includes urinalysis, symptom questionnaires like the International Prostate Symptom Score IPSS, ECGs, vital signs, and tracking of adverse events including suicidal ideation or behavior. These measures will be collected throughout the 12-month study to evaluate both safety and urinary function.

CONDITIONS

Brief Title

A Study to Evaluate the Effect of KarXT on Urological Safety

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here